An observational study in Critical Illness, Obesity & Overweight and Mortality in Intensive Care Units, sponsored by Ondokuz Mayıs University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Ondokuz Mayıs University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Ondokuz Mayıs University — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Ondokuz Mayıs University.
Among the 10 studies in Obesity by Ondokuz Mayıs University, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 10th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →4 of the 10 studies in Obesity by Ondokuz Mayıs University are open now, in 1 country. Recruiting first, the newest first:
Ondokuz Mayıs University · Sites in Turkey
Ages 18–65 · Women only · Healthy volunteers
Ondokuz Mayıs University
Ages 18–65 · Women only
Ondokuz Mayıs University · Sites in Turkey
Ages 65–85 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 54 across the 7 interventional studies, 93 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.
1 of the studies in Obesity by Ondokuz Mayıs University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07631429Ondokuz Mayıs UniversityBody Roundness Index and Mortality in ICU Patients | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Ondokuz Mayıs University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates whether Body Roundness Index (BRI), an anthropometric measure derived from waist circumference and height, can predict mortality in adult intensive care unit (ICU) patients. BRI captures central adiposity and body fat distribution more accurately than Body Mass Index (BMI). In this prospective multicenter cohort study, BRI will be measured at ICU admission and its association with ICU mortality, 28-day mortality, hospital mortality, mechanical ventilation duration, ICU length of stay, and acute kidney injury will be evaluated. The predictive performance of BRI will also be compared with BMI.
Body Roundness Index (BRI) is calculated using waist circumference and height, and reflects central adiposity more precisely than BMI. Despite growing evidence supporting BRI as a cardiovascular and metabolic risk predictor in general populations, its prognostic value in critically ill patients remains unexplored.
In this prospective multicenter cohort study, adult patients admitted to participating ICUs will be enrolled. Waist circumference will be measured using a standardized protocol (supine position, iliac crest landmark, end-expiration, inelastic tape, 0.1 cm precision) within 24 hours of ICU admission. BRI will be calculated using the formula: 364.2 - 365.5 × √(1 - ((WC/2π)² / (0.5×height)²)).
The primary outcome is ICU mortality. Secondary outcomes include 28-day mortality, hospital mortality, mechanical ventilation duration, ICU length of stay, and new acute kidney injury (KDIGO stage ≥2). The shape of the BRI-mortality relationship will be assessed using restricted cubic splines. BRI and BMI will be compared head-to-head for discriminative performance. Subgroup analyses will include sepsis patients to evaluate whether BRI resolves the obesity paradox observed with BMI.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 550 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Browse Obesity studies →Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients admitted to the intensive care units of participating tertiary care centers in Turkey. Enrollment will be conducted prospectively across multiple centers following ethics committee approval at each site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients (≥18 years) admitted to the intensive care unit with an expected stay of ≥24 hours. Waist circumference and height are measured within 24 hours of admission to calculate Body Roundness Index (BRI) and BMI. Patients are followed for ICU mortality, 28-day mortality, hospital mortality, mechanical ventilation duration, ICU length of stay, and acute kidney injury (KDIGO stage ≥2). No intervention is applied; this is a prospective observational cohort.
ICU Mortality
Death occurring during ICU stay, assessed from admission to ICU discharge or death, whichever comes first.
Time frame: From ICU admission to ICU discharge or death, up to 28 days.
28-Day Mortality
All-cause mortality within 28 days of ICU admission.
Time frame: 28 days from ICU admission.
Hospital Mortality
Death occurring during hospital stay
Time frame: From ICU admission to hospital discharge or death, up to 90 days.
Mechanical Ventilation Duration
Total days of invasive mechanical ventilation during ICU stay.
Time frame: From ICU admission to ICU discharge, up to 28 days.
ICU Length of Stay
Total number of days spent in the ICU
Time frame: From ICU admission to ICU discharge, up to 28 days.
Number of Participants with New Acute Kidney Injury (KDIGO Stage ≥2)
New AKI development defined as KDIGO stage ≥2 during ICU stay.
Time frame: From ICU admission to ICU discharge, up to 28 days.
Plan to share: Yes — De-identified individual participant data underlying published results will be made available upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 6 months after primary results publication, available for 2 years.
Access criteria: Researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author. Data will be shared after signing a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 12 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.